Related references
Note: Only part of the references are listed.Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
Johan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review
Fabio Efficace et al.
LEUKEMIA RESEARCH (2013)
Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia
Michael J. Mauro
LEUKEMIA RESEARCH (2013)
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
Kristin M. Phillips et al.
SUPPORTIVE CARE IN CANCER (2013)
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group
Fabio Efficace et al.
ANNALS OF HEMATOLOGY (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia
Juan Luis Steegmann et al.
LEUKEMIA & LYMPHOMA (2012)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
Karl J. Aichberger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia
D. Dumitrescu et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR
V. G. Oehler et al.
LEUKEMIA (2009)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
EA Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
